Get the Stockscreener App
3.9637
4.47%
-0.1763
Abcellera Biologics Inc stock is traded at $3.9637, with a volume of 2.19M.
It is down -4.47% in the last 24 hours and up +10.47% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$4.14
Open:
$4.16
24h Volume:
2.19M
Relative Volume:
0.51
Market Cap:
$1.19B
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-7.6225
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-4.93%
1M Performance:
+10.47%
6M Performance:
-22.60%
1Y Performance:
+17.71%
1-Day Range:
$3.95
$4.25
1-Week Range:
$3.95
$4.85
52-Week Range:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.9637 | 1.24B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.94 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.19 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.23 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn
Strategic Moves Shape ABCL’s Market Position - StocksToTrade
AbCellera’s Market Moves: Key Developments - timothysykes.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat
Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside - directorstalkinterviews.com
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Investing News Network
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial - Sahm
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st
Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance
AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat
AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL6 - PharmiWeb.com
AbCellera (ABCL) Advances Clinical Trial for Menopause Treatment - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade - MarketBeat
Bear Alert: Is AbCellera Biologics Inc stock forming a triangle patternJuly 2025 Drop Watch & Smart Allocation Stock Tips - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Rating Increased to Hold at Wall Street Zen - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After Bruker Settlement And Board Appointment - simplywall.st
Will AbCellera Biologics Inc. stock return to pre crisis levels2025 Pullback Review & Weekly Watchlist of Top Performers - ulpravda.ru
Can AbCellera Biologics Inc. stock maintain operating marginsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
AbCellera Biologics (ABCL) Is Up 20.8% After Bruker Settlement Win And Board AdditionWhat's Changed - simplywall.st
How AbCellera Biologics Inc. stock performs in weak economyJuly 2025 WrapUp & Safe Capital Growth Plans - Улправда
Can AbCellera Biologics Inc. stock hit analyst price targetsMarket Correction Analysis & Maximize Returns With Insights - Улправда
AbCellera (ABCL) Loses Chief Commercial Officer to Viking Therap - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Trading Up 9.2%Still a Buy? - MarketBeat
AbCellera settles patent litigation with Bruker over microfluidic device tech - MSN
AbCellera Biologics (NASDAQ:ABCL) Cut to Sell at Wall Street Zen - MarketBeat
Is AbCellera Biologics Inc a good long term investmentMid Cap Growth Trends & These 3 Stocks Could Change Your Portfolio - earlytimes.in
MACD Cross Could Confirm Trend in Sancode Technologies LimitedEmerging Market Stocks & Unlock Patterns Humans Can’t See - earlytimes.in
Update Recap: How AbCellera Biologics Inc stock performs in weak economyExit Point & Real-Time Volume Analysis Alerts - moha.gov.vn
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Upgraded at Wall Street Zen - MarketBeat
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn - Yahoo Finance
AbCellera: Losing Its Undeserved Premium (NASDAQ:ABCL) - Seeking Alpha
AbCellera Appoints Dr. Stephen Quake to Board - MSN
Why AbCellera Biologics Inc. stock is in analyst buy zoneMarket Activity Report & High Accuracy Investment Entry Signals - Улправда
Can AbCellera Biologics Inc. stock beat analyst upgrades2025 Trading Volume Trends & Verified Stock Trade Ideas - Улправда
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - MSN
AbCellera Biologics (STU:8QQ) EV-to-OCF : -6.77 (As of Dec. 22, 2025) - GuruFocus
AbCellera Gets $36M In Cell Research Patent Settlement - Law360
Buyout Rumor: How AbCellera Biologics Inc. stock performs in weak economyCEO Change & Weekly High Potential Alerts - DonanımHaber
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):